Bicycle Therapeutics plc (NASDAQ:BCYC) Given Average Recommendation of "Moderate Buy" by Analysts

Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $29.14.

A number of equities research analysts have recently issued reports on BCYC shares. Stephens reiterated an "equal weight" rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. Needham & Company LLC reiterated a "buy" rating and set a $30.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. B. Riley reduced their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. HC Wainwright restated a "buy" rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Finally, JMP Securities cut their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a research report on Wednesday, December 18th.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CEO Kevin Lee sold 9,038 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $127,345.42. Following the completion of the sale, the chief executive officer now directly owns 495,026 shares of the company's stock, valued at approximately $6,974,916.34. The trade was a 1.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 985,397 shares of the stock in a transaction on Friday, December 13th. The stock was purchased at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the purchase, the director now directly owns 9,537,643 shares in the company, valued at $131,237,967.68. This trade represents a 11.52 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 27,677 shares of company stock valued at $392,413. Company insiders own 8.50% of the company's stock.

Institutional Trading of Bicycle Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Baker BROS. Advisors LP grew its stake in shares of Bicycle Therapeutics by 15.8% during the 4th quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock valued at $152,395,000 after buying an additional 1,485,397 shares during the period. Point72 Asset Management L.P. grew its stake in shares of Bicycle Therapeutics by 406.2% during the 4th quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company's stock valued at $63,769,000 after buying an additional 3,655,101 shares during the period. Fcpm Iii Services B.V. grew its stake in shares of Bicycle Therapeutics by 47.5% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company's stock valued at $48,333,000 after buying an additional 1,112,369 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of Bicycle Therapeutics by 21.5% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company's stock valued at $41,887,000 after buying an additional 327,089 shares during the period. Finally, Candriam S.C.A. grew its stake in shares of Bicycle Therapeutics by 3.5% during the 4th quarter. Candriam S.C.A. now owns 1,087,876 shares of the company's stock valued at $15,230,000 after buying an additional 37,278 shares during the period. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Price Performance

Shares of BCYC stock traded down $0.50 during midday trading on Friday, reaching $10.47. 173,771 shares of the company traded hands, compared to its average volume of 298,289. The firm's 50 day simple moving average is $13.19 and its two-hundred day simple moving average is $19.27. Bicycle Therapeutics has a 1-year low of $10.38 and a 1-year high of $28.67. The firm has a market cap of $722.91 million, a PE ratio of -3.18 and a beta of 0.93.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. During the same period last year, the firm earned ($1.16) EPS. The company's revenue for the quarter was down 30.2% on a year-over-year basis. As a group, research analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.